Portal


Dr Khasha Ghaffarzadeh
Dr Khasha Ghaffarzadeh
IDTechEx
+44 (0)1223 812300
Email Analyst
Sichuan Revotek Co. Ltd.
 

Sichuan Revotek Co. Ltd.

Sichuan Revotek IDTechEx analyst Nadia Tsao interviewed Sichuan Revotek representative Dun Liu on February 16, 2017. The company is developing a 3D bioprinting technology that utilises the patient's own stem cells to grow vascular grafts. History Established in 2014, Sichuan Revotek is a 3D bioprinting company that aims to provide precision medicine and personalised healthcare to patients around the world. The company was founded as a result of {#yen}200 million in funding from Sichuan Languang Development Co., a real estate company in China, which in turn owns 60% of Sichuan Revotek. The company is headed by it's CEO/CSO, Dr James Kang, a research physician with experience in cardiology, toxicology, and regenerative medicine. Sichuan Revotek started its research into regenerative medicine by initiating the Biosynsphere R&D project in 2014. The resulting technology (profiled below) is used in the formation of the bioink used in Sichuan Revotek's 3D bioprinter. As such, the Biosynsphere is effectively the core of the Sichuan Revotek bioprinting system. The rest of the system was launched in 2015, and includes the RevoPrinter, a 3D bioprinter for blood vessels, and the RevoCloud software. In 2016, Sichuan Revotek initiated a pre-clinical trial in 30 rhesus monkeys. Bioprinted blood vessels grown from the monkey's own stem cells were grafted into their abdominal artery. By December 2016, the study was deemed a success - the bioprinted grafts were fully accepted with 100% patency and were indistinguishable from existing vasculature. This made Sichuan Revotek the first in the world to successfully 3D bioprint and implant a vascular graft constructed from autologous adipose-derived stem cells. At the time of our interview in February 2017, Sichuan Revotek had already begun preparations for a clinical trial of its technology in either the USA or China. So far, the company has started negotiations with potential trial sites (hospitals), and are in the process of submitting to the FDA for approval. To support this translational research, the company aims to set up bases in universities in the USA and UK, but will keep its R&D base in Chengdu, China. Sichuan Revotek